Literature DB >> 24288035

Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Barbara Connolly1, Susan H Fox.   

Abstract

Neuropsychiatric symptoms are common in Parkinson's disease (PD) and add significantly to the burden of disease. These symptoms are most commonly part of the disease spectrum owing to pathological changes within relevant brain regions. Neuropsychiatric problems include disorders of cognition, ranging from mild cognitive impairment to dementia, psychotic symptoms, including, most commonly, well-formed visual hallucinations and paranoid delusions, and mood disorders, such as depression and anxiety. The other common cause of neuropsychiatric problem is secondary to use of dopaminergic drugs. Some PD patients may develop behavioral disorders, including impulse control disorders (ICDs) and addictive symptoms. Psychosis can be due to a mixture of underlying pathology, with triggering or worsening of symptoms with changes to PD medications. Currently, management of these disorders primarily uses therapies developed for general psychiatry and cognitive neurology, rather than specifically for PD. However, significant adverse effects, such as worsening of the motor symptoms of PD, can limit use of some drug therapies. Identification of drug-induced symptoms, such as ICDs, enables withdrawal of the offending drug as the principal management strategy. Research is ongoing in an effort to develop more specific therapies for PD-related neuropsychiatric symptoms.

Entities:  

Mesh:

Year:  2014        PMID: 24288035      PMCID: PMC3899484          DOI: 10.1007/s13311-013-0238-x

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  170 in total

1.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

2.  Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits.

Authors:  L Schilbach; P H Weiss; J Kuhn; L Timmermann; J Klosterkötter; W Huff
Journal:  Neurocase       Date:  2011-09-15       Impact factor: 0.881

Review 3.  Neurobiology of cognitive impairment in Parkinson's disease.

Authors:  Kurt A Jellinger
Journal:  Expert Rev Neurother       Date:  2012-12       Impact factor: 4.618

4.  A 12-year population-based study of psychosis in Parkinson disease.

Authors:  Elin B Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Christopher G Goetz; Glenn T Stebbins; Dag Aarsland; Guido Alves
Journal:  Arch Neurol       Date:  2010-08

5.  Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease.

Authors:  Juan Carlos Gómez-Esteban; Beatriz Tijero; Johanne Somme; Roberto Ciordia; Koldo Berganzo; Idoia Rouco; Jose Luis Bustos; Maria Antonia Valle; Elena Lezcano; Juan J Zarranz
Journal:  J Neurol       Date:  2010-10-19       Impact factor: 4.849

6.  Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers.

Authors:  David Okai; Sally Askey-Jones; Michael Samuel; Sean S O'Sullivan; K Ray Chaudhuri; Anne Martin; Joel Mack; Richard G Brown; Anthony S David
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

7.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

8.  Apathy in patients with Parkinson disease as a function of side of onset.

Authors:  Erica Harris; Patrick McNamara; Raymon Durso
Journal:  J Geriatr Psychiatry Neurol       Date:  2013-04-12       Impact factor: 2.680

9.  Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom.

Authors:  Virginie Czernecki; Michael Schüpbach; Sadek Yaici; Richard Lévy; Eric Bardinet; Jérôme Yelnik; Bruno Dubois; Yves Agid
Journal:  Mov Disord       Date:  2008-05-15       Impact factor: 10.338

Review 10.  Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment.

Authors:  Gabriella Santangelo; Luigi Trojano; Paolo Barone; Domenico Errico; Dario Grossi; Carmine Vitale
Journal:  Behav Neurol       Date:  2013-01-01       Impact factor: 3.342

View more
  24 in total

1.  Editorial: Neurotherapeutics of movement disorders.

Authors:  Stewart A Factor; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease.

Authors:  N R Williams; B S Bentzley; G L Sahlem; J Pannu; J E Korte; G Revuelta; E B Short; M S George
Journal:  Acta Neurol Scand       Date:  2016-05-31       Impact factor: 3.209

Review 3.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

Review 4.  Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.

Authors:  Daniel Martinez-Ramirez; Michael S Okun; Michael S Jaffee
Journal:  Neurodegener Dis Manag       Date:  2016-07-13

5.  Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).

Authors:  Kimberley A Phillips; Corinna N Ross; Jennifer Spross; Catherine J Cheng; Alyssa Izquierdo; K C Biju; Cang Chen; Senlin Li; Suzette D Tardif
Journal:  Behav Brain Res       Date:  2017-02-17       Impact factor: 3.332

Review 6.  Towards understanding neural network signatures of motor skill learning in Parkinson's disease and healthy aging.

Authors:  Evelien Nackaerts; Nicholas D'Cruz; Bauke W Dijkstra; Moran Gilat; Thomas Kramer; Alice Nieuwboer
Journal:  Br J Radiol       Date:  2019-05-14       Impact factor: 3.039

7.  The impact of motor symptoms on self-reported anxiety in Parkinson's disease.

Authors:  Robert D Salazar; Asher M Le; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Parkinsonism Relat Disord       Date:  2017-01-24       Impact factor: 4.891

8.  Temporal Dissociation of Striatum and Prefrontal Cortex Uncouples Anhedonia and Defense Behaviors Relevant to Depression in 6-OHDA-Lesioned Rats.

Authors:  Filipe C Matheus; Daniel Rial; Joana I Real; Cristina Lemos; Reinaldo N Takahashi; Leandro J Bertoglio; Rodrigo A Cunha; Rui D Prediger
Journal:  Mol Neurobiol       Date:  2015-07-12       Impact factor: 5.590

Review 9.  [Parkinson's disease in the elderly].

Authors:  Rüdiger Lange; Frank Erbguth
Journal:  Z Gerontol Geriatr       Date:  2017-07-19       Impact factor: 1.281

Review 10.  Cognitive Behavioral Therapy in Movement Disorders: A Review.

Authors:  Isabella Berardelli; Massimo Pasquini; Valentina Roselli; Massimo Biondi; Alfredo Berardelli; Giovanni Fabbrini
Journal:  Mov Disord Clin Pract       Date:  2015-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.